中国药房2024，Vol.35Issue(14)：1790-1794,5.DOI:10.6039/j.issn.1001-0408.2024.14.21
钠-葡萄糖耦联转运体2抑制剂的药物基因组学研究进展
Study progress on pharmacogenomics of sodium-glucose linked transporter 2 inhibitors
摘要
Abstract
Sodium-glucose linked transporter 2 inhibitors(SGLT2i)are novel oral hypoglycaemic agents and are widely used for hypoglycemic therapy in patients with type 2 diabetes mellitus,but differences in the genetic backgrounds of patients often lead to variable responsiveness to drug therapy.By summarizing the pharmacogenomic studies of SGLT2i,the article found that the genetic variants of UGT1A9,UGT2B4,SLC5A2,ABCB1,PNPLA3 and WFS1 may influence the pharmacokinetics of SGLT2i and the external hypoglycemic effects of SGLT2i in improving non-alcoholic fatty liver disease,weight loss and so on,but there is no clinical evidence that genetic polymorphisms affect the hypoglycemic efficacy of SGLT2i.关键词
基因多态性/钠-葡萄糖耦联转运体2抑制剂/个体差异/药物基因组学/药代动力学/药效动力学Key words
gene polymorphism/SGLT2i/individual differences/pharmacogenomics/pharmacokinetics/pharmacodynamics分类
医药卫生引用本文复制引用
庄永如,宋金方..钠-葡萄糖耦联转运体2抑制剂的药物基因组学研究进展[J].中国药房,2024,35(14):1790-1794,5.基金项目
国家自然科学基金项目(No.82204536) （No.82204536）
无锡市第二届"双百"中青年医疗卫生拔尖人才计划(No.HB2023064) （No.HB2023064）
